Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim with Docetaxel and Prednisone in HRPC
NCT00313482Phase 2Terminated
- Sponsor
- Veeda Lifesciences
- Start
- Apr 2006
- Primary completion
- Aug 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sargramostim in prostate cancer (PCa), sponsored by Veeda Lifesciences. Primary endpoint: Progression-Free Survival. Started Apr 2006; status: terminated.
02
Drugs
sargramostim
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00313482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313482.